Q-omics provides the consensus-scored TBCCD1 profile across patient tissues and cancer cell-line models. TBCCD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TBCCD1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TBCCD1 RNA expression shows 20,449 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where TBCCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBCCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBCCD1 survival associations across molecular data types. TBCCD1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBCCD1 RNA expression–survival associations across cancer types. High TBCCD1 expression shows unfavorable associations in ACC, PAAD, LGG, LIHC and KICH, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TBCCD1 RNA expression.
This table summarizes TBCCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TBCCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBCCD1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and LUSC. The HNSC box plot shows higher TBCCD1 RNA expression in tumor versus normal tissue (log2 FC = +1.079, t-test p < 0.001).
This table shows molecular features associated with TBCCD1 in patient tissues and cancer cell lines. In patient samples, TBCCD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBCCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
